Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology

Jiachang Gong, Jinping Gan, Eric Masson, S. Syed, Yuanqing Xia, Daphne Williams, Janice Pursley, Mohammed Jemal, William G. Humphreys, Ramaswamy A. IyerDrug 2012 · DOI

TL;DR

This study investigates the metabolic chiral inversion of brivanib, a cancer drug candidate, revealing that it can flip its stereochemistry in the body. While this inversion is significant in animals, it's minimal in humans, suggesting a potentially lower risk of unexpected side effects or altered efficacy from this specific metabolic pathway in humans.

What Problem Does This Paper Address?

Many drugs are chiral, meaning they exist as non-superimposable mirror images (enantiomers). Often, only one enantiomer has the desired therapeutic effect, while the other might be inactive or even harmful. Ideally, a drug should maintain its intended stereochemistry in the body. However, some drugs can undergo "chiral inversion," where one enantiomer is converted into the other. This can lead to unexpected pharmacological effects or safety concerns if the inverted enantiomer has different properties. Brivanib, a dual inhibitor of VEGF and FGF signaling pathways used in cancer treatment, has a chiral center. The problem this paper addresses is understanding whether brivanib undergoes chiral inversion, how this process occurs, and what its implications are for the drug's safety and pharmacology, especially when comparing animal models to humans.

Methods

The researchers employed a multi-pronged approach to investigate brivanib's chiral inversion:

  • In Vitro Incubations: Liver subcellular fractions (microsomes and cytosols) from rats, monkeys, and humans were incubated with radiolabeled brivanib alaninate. This allowed them to observe metabolic transformations in a controlled laboratory setting.
  • Chiral Chromatography (LC/MS): This was a key technique. Standard liquid chromatography (LC) separates compounds based on their chemical properties. Chiral LC, however, uses specialized columns that can distinguish between enantiomers, allowing researchers to quantify the amount of brivanib and its inverted enantiomer formed.
  • In Vivo Studies: Brivanib alaninate was administered orally to rats, monkeys, and human volunteers. Blood samples were collected over time to measure the concentrations of brivanib and its enantiomer in plasma.
  • Pharmacological Assays: In vitro kinase inhibition and cell proliferation assays were conducted to compare the biological activity of brivanib and its enantiomer.

Datasets

Not discussed in the paper. The study relies on experimental data generated from incubations and in vivo studies, rather than pre-existing datasets.

Key Insights and Ideas

  • Chiral Inversion is Real for Brivanib: The study definitively shows that brivanib can indeed undergo chiral inversion, converting from its original (R)-configuration to its (S)-enantiomer.
  • A Two-Step Mechanism: The proposed mechanism involves oxidation of the chiral alcohol to a ketone, followed by reduction back to a mixture of the original enantiomer and its inverted form. This is a common pathway for chiral inversion of secondary alcohols.
  • Species Differences are Crucial: The extent of chiral inversion and the resulting exposure to the enantiomer vary dramatically between species. This highlights the importance of cross-species comparisons in drug development.
  • NADPH is Key: The chiral inversion process in liver microsomes and cytosols was largely dependent on NADPH, a crucial cofactor in many metabolic reactions.
  • Bidirectional but Asymmetric: While the inversion is bidirectional (the enantiomer can also convert back to brivanib), the conversion of brivanib to its enantiomer is significantly more efficient than the reverse process.

Key Results

  • In Vitro: In microsomal incubations, the conversion of brivanib to its enantiomer ranged from 11.6-15.8% across species in the presence of NADPH. Cytosolic incubations showed lower inversion rates (0.8-3.1%).
  • In Vivo (Animals): In rats and monkeys, the enantiomeric metabolite was a prominent circulating component after oral administration. In rats, the area under the curve (AUC) of the enantiomer was 94.7% of brivanib's AUC. In monkeys, it was 39.7%.
  • In Vivo (Humans): In contrast, the enantiomeric metabolite was a minor circulating component in humans, with an AUC of only 1.6% relative to brivanib.
  • Pharmacological Potency: Brivanib and its enantiomer exhibited similar potency in inhibiting VEGFR-2 and FGFR-1 kinases, and in inhibiting cell proliferation.

Limitations and Future Work

  • Enzyme Identification: While the study identified the involvement of microsomal and cytosolic enzymes and the cofactor NADPH, the specific enzymes responsible for the oxidation and reduction steps were not identified. Future work could focus on pinpointing these enzymes.
  • Human Enantiomer Exposure: The low exposure of the enantiomeric metabolite in humans was surprising given the in vitro findings. The authors suggest that higher systemic clearance in humans, possibly mediated by metabolism or active transport, could explain this. Further studies on transporter roles are recommended.
  • Toxicology of Enantiomer: While the study suggests adequate toxicological coverage due to low human exposure, the direct toxicology of the enantiomeric metabolite was not specifically studied in preclinical species.
  • Clinical Relevance of Low Human Exposure: Given the similar pharmacological potency of both enantiomers, the low human exposure of the enantiomer suggests it's unlikely to significantly contribute to the overall pharmacology of brivanib, which is a positive finding for safety. However, understanding the precise reasons for the species difference in exposure remains an area for further investigation.

Summary updated

BibTeX
@inproceedings{gong2012metabolic,
  author = {Jiachang Gong and Jinping Gan and Eric Masson and S. Syed and Yuanqing Xia and Daphne Williams and Janice Pursley and Mohammed Jemal and William G. Humphreys and Ramaswamy A. Iyer},
  title = {{Metabolic Chiral Inversion of Brivanib and Its Relevance to Safety and Pharmacology}},
  booktitle = {Drug},
  year = {2012},
  doi = {10.1124/dmd.112.047340},
}
Figure